The Financial Select Sector SPDR Fund (XLF)
- Previous Close
47.13 - Open
47.07 - Bid 46.55 x 1000
- Ask --
- Day's Range
46.48 - 47.21 - 52 Week Range
33.46 - 47.81 - Volume
49,455,391 - Avg. Volume
35,255,803 - Net Assets 42.11B
- NAV 46.52
- PE Ratio (TTM) 21.09
- Yield 1.47%
- YTD Daily Total Return 25.02%
- Beta (5Y Monthly) 1.02
- Expense Ratio (net) 0.09%
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Financial companies by the Global Industry Classification Standard, including securities of companies from the following industries: financial services; insurance; banks; capital markets; mortgage real estate investment trusts; and consumer finance. The fund is non-diversified.
SPDR State Street Global Advisors
Fund Family
Financial
Fund Category
42.11B
Net Assets
1998-12-16
Inception Date
Performance Overview: XLF
View MoreTrailing returns as of 10/31/2024. Category is Financial.
People Also Watch
Holdings: XLF
View MoreTop 10 Holdings (53.90% of Total Assets)
Sector Weightings
Recent News: XLF
View MoreResearch Reports: XLF
View MoreMeta Earnings: Powerful Advertising Engine Continues to Chug Along
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm’s “Family of Apps,” its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta’s overall sales.
RatingPrice TargetBiogen Earnings: Full-Year Guidance Raised; Early Leqembi Sales Encouraging but Uncertainty Remains
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetTesla Earnings: Margin Recovery Underway as Long-Term Objectives Intact
Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling more affordable vehicles, a sports car, and a robotaxi. Global deliveries in 2023 were a little over 1.8 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.
RatingPrice TargetNetflix Earnings: Signs of Subscriber Growth Normalization, but Sales and Margins Remain Impressive
Netflix’s relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 280 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm recently began introducing ad-supported subscription plans, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.
RatingPrice Target